Exogenous Surfactant Through Nebulizer Mask on Clinical Outcomes in Covid-19 Patients
Status:
Not yet recruiting
Trial end date:
2021-09-20
Target enrollment:
Participant gender:
Summary
Covid-19 disease is one of the most important health system challenges which is the result of
the recent SARS CoV-2 virus outbreak. So far, despite the use of different types of
pharmaceuticals, none has been served as a curative treatment and research is continued to
find one or more effective drugs; either palliative or curative ones.
One of the most important clinical problems in Covid-19 patients is lung involvement, which
may causes significant sequels; leading to a main part of morbidity and/or mortality.
Surfactant is one of the drugs that can have valuable effects on the lungs, both by reducing
the alveolar surface tension and by exerting immunomodulatory effects.
In a previous study by the same team, favorable effects were seen in intubated patients;
however, the aim of this study was to evaluate the effect of exogenous nebulized surfactant
in the pre-intubation stages of the disease.